MAIA Pharmaceuticals

MAIA Pharmaceuticals develops, manufactures, and markets innovative niche generic pharmaceutical products with a focus on injectables, diagnostics agents, hormones, oncology therapeutics, and hospital-use medications. Its portfolio includes both small molecules and synthetic peptides for approved indications such as heparin-induced thrombocytopenia/thrombosis treatment with bivalirudin injection—recently commercialized through a partnership with Endo—and diagnostic imaging using cholecystokinin analogs. The company has also filed patents related to excipients and experimental cancer drugs but does not appear to have proprietary new chemical entities or novel biologic platforms.